etidronate has been researched along with Ectopic Hormone Syndromes in 6 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of intravenous etidronate disodium (etidronate) in controlling hypercalcemia of malignancy, 20 patients with known malignant disease and hypercalcemia were randomly assigned on a two-to-one basis to receive etidronate, 7." | 9.06 | Etidronate disodium in the management of malignancy-related hypercalcemia. ( Charles, P; Hasling, C; Mosekilde, L, 1987) |
| "Following a four-day control period during which an elevated serum calcium level either stabilized or continued to rise despite maximally tolerated saline diuresis, 12 patients with neoplastic hypercalcemia were treated with intravenous etidronate disodium (etidronate) 7." | 7.67 | Neoplastic hypercalcemia: physiologic response to intravenous etidronate disodium. ( Clemens, TL; Gordon, AC; Gundberg, CM; Jacobs, TP; Reich, L; Shane, E; Silverberg, SJ, 1987) |
| "Nineteen patients with Paget's disease and four patients with hypercalcemia of malignancy underwent hypocalcemic therapy with etidronate disodium (etidronate) administered intravenously." | 7.67 | Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Effects on biochemical parameters and bone histomorphometry. ( Arlot, M; Chapuy, MC; Charhon, S; Delmas, P; Edouard, C; Meunier, PJ, 1987) |
| "To evaluate the efficacy of intravenous etidronate disodium (etidronate) in controlling hypercalcemia of malignancy, 20 patients with known malignant disease and hypercalcemia were randomly assigned on a two-to-one basis to receive etidronate, 7." | 5.06 | Etidronate disodium in the management of malignancy-related hypercalcemia. ( Charles, P; Hasling, C; Mosekilde, L, 1987) |
| "Following a four-day control period during which an elevated serum calcium level either stabilized or continued to rise despite maximally tolerated saline diuresis, 12 patients with neoplastic hypercalcemia were treated with intravenous etidronate disodium (etidronate) 7." | 3.67 | Neoplastic hypercalcemia: physiologic response to intravenous etidronate disodium. ( Clemens, TL; Gordon, AC; Gundberg, CM; Jacobs, TP; Reich, L; Shane, E; Silverberg, SJ, 1987) |
| "Nineteen patients with Paget's disease and four patients with hypercalcemia of malignancy underwent hypocalcemic therapy with etidronate disodium (etidronate) administered intravenously." | 3.67 | Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Effects on biochemical parameters and bone histomorphometry. ( Arlot, M; Chapuy, MC; Charhon, S; Delmas, P; Edouard, C; Meunier, PJ, 1987) |
| "Etidronate was also found to prevent bone metastasis in syngeneic rat mammary carcinoma." | 1.27 | Effect of etidronate disodium on the interactions between malignancy and bone. ( Garattini, S; Guaitani, A; Mantovani, A, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jacobs, TP | 1 |
| Gordon, AC | 1 |
| Silverberg, SJ | 1 |
| Shane, E | 1 |
| Reich, L | 1 |
| Clemens, TL | 1 |
| Gundberg, CM | 1 |
| Canfield, RE | 1 |
| Hasling, C | 1 |
| Charles, P | 1 |
| Mosekilde, L | 1 |
| Garattini, S | 1 |
| Guaitani, A | 1 |
| Mantovani, A | 1 |
| Meunier, PJ | 1 |
| Chapuy, MC | 1 |
| Delmas, P | 1 |
| Charhon, S | 1 |
| Edouard, C | 1 |
| Arlot, M | 1 |
1 trial available for etidronate and Ectopic Hormone Syndromes
| Article | Year |
|---|---|
Etidronate disodium in the management of malignancy-related hypercalcemia.
Topics: Adult; Aged; Calcium; Double-Blind Method; Etidronic Acid; Female; Humans; Hypercalcemia; Male; Midd | 1987 |
5 other studies available for etidronate and Ectopic Hormone Syndromes
| Article | Year |
|---|---|
Neoplastic hypercalcemia: physiologic response to intravenous etidronate disodium.
Topics: Adult; Aged; Aged, 80 and over; Calcifediol; Calcitriol; Calcium; Creatinine; Cyclic AMP; Etidronic | 1987 |
Rationale for diphosphonate therapy in hypercalcemia of malignancy. Introduction.
Topics: Bone Neoplasms; Etidronic Acid; Humans; Hypercalcemia; Kidney; Osteoclasts; Paraneoplastic Endocrine | 1987 |
Etidronate disodium: a new therapy for hypercalcemia of malignancy. Proceedings of a symposium.
Topics: Etidronic Acid; Humans; Hypercalcemia; Neoplasms; Paraneoplastic Endocrine Syndromes | 1987 |
Effect of etidronate disodium on the interactions between malignancy and bone.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Etidronic Acid; Hypercalcemia; Mice; Osteolysis; Par | 1987 |
Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Effects on biochemical parameters and bone histomorphometry.
Topics: Bone and Bones; Calcium; Etidronic Acid; Humans; Hypercalcemia; Osteitis Deformans; Paraneoplastic E | 1987 |